Gravitate Health FHIR Implementation Guide, published by Gravitate Health Project. This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/joofio/test-epi-composition/ and changes regularly. See the Directory of published versions
Full name:
Authorised dose form:
Legal status of supply:
Domain:
Resource status:
Product classification:
Document Details
Generated Narrative: Bundle TEST PURPOSES ONLY - vizarsin
Language: en
Profile: Bundle - ePI
Final Document at 2022-02-16 13:28:17+0000 by Organization ACME industry for Bundle: identifier = http://ema.europa.eu/identifier#None; type = document; timestamp = 2023-06-27 10:09:22+0000
Document Subject
Generated Narrative: MedicinalProductDefinition mp4f21ade1d3a44922f890a931e55ca9a9
identifier: http://ema.europa.eu/identifier
/1 film-coated tablet: EU/1/09/551/001
type: Medicinal Product
domain: Human use
status: active
legalStatusOfSupply: Medicinal product subject to medical prescription
name
productName: Vizarsin 25 mg film-coated tablets
type: Full name
part
part: nan
type: Invented name part
part
part: nan
type: Scientific name part
part
part: nan
type: Strength part
part
part: nan
type: Pharmaceutical dose form part
Usages
Country Jurisdiction Language EU EU en
Document Content
Generated Narrative: Composition composition-en-4f21ade1d3a44922f890a931e55ca9a9
Language: en
Profile: Composition (ePI)
identifier: http://ema.europa.eu/identifier
/1 film-coated tablet: EU/1/09/551/001
status: Final
type: Package Leaflet
category: Raw
date: 2022-02-16 13:28:17+0000
author: Organization ACME industry
title: TEST PURPOSES ONLY - vizarsin
Mode | Time |
Official | 2022-02-16 13:28:17+0000 |
What is in this leaflet
Vizarsin contains the active substance sildenafil which belongs to a group of medicines called phosphodiesterase type 5 (PDE5) inhibitors. It works by helping to relax the blood vessels in your penis, allowing blood to flow into your penis when you get sexually excited. Vizarsin will only help you to get an erection if you are sexually stimulated. Vizarsin is a treatment for adult men with erectile dysfunction, sometimes known as impotence. This is when a man cannot get, or keep a hard, erect penis suitable for sexual activity.
If you experience sudden decrease or loss of vision, stop taking Vizarsin and contact your doctor immediately. You should not use Vizarsin with any other oral or local treatments for erectile dysfunction. You should not use Vizarsin with treatments for pulmonary arterial hypertension (PAH) containing sildenafil or any other PDE5 inhibitors. You should not take Vizarsin if you do not have erectile dysfunction. You should not take Vizarsin if you are a woman. Special considerations for patients with kidney or liver problems You should tell your doctor if you have kidney or liver problems. Your doctor may decide on a lower dose for you. Children and adolescents Vizarsin should not be given to individuals under the age of 18. Other medicines and Vizarsin Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. Vizarsin tablets may interfere with some medicines, especially those used to treat chest pain. In the event of a medical emergency, you should tell your doctor, pharmacist or nurse that you have taken Vizarsin and when you did. Do not take Vizarsin with other medicines unless your doctor tells you that you can. You should not take Vizarsin if you are taking medicines called nitrates, as the combination of these medicines may lead to a dangerous fall in your blood pressure. Always tell your doctor, pharmacist or nurse if you are taking any of these medicines that are often used for the relief of angina pectoris (or chest pain ). You should not take Vizarsin if you are using any of the medicines known as nitric oxide donors such as amyl nitrite ( poppers ) as the combination may also lead to a dangerous fall in your blood pressure. Tell your doctor or pharmacist if you are already taking riociguat. If you are taking medicines known as protease inhibitors, such as for the treatment of HIV, your doctor may start you on the lowest dose (25 mg) of Vizarsin. Some patients who take alpha-blocker therapy for the treatment of high blood pressure or prostate enlargement may experience dizziness or light-headedness, which may be caused by low blood pressure upon sitting or standing up quickly. Certain patients have experienced these symptoms when taking Vizarsin with alpha-blockers. This is most likely to happen within 4 hours after taking Vizarsin. To reduce the chance that these symptoms might happen, you should be on a regular daily dose of your alpha-blocker before you start Vizarsin. Your doctor may start you on a lower dose (25 mg) of Vizarsin. Tell your doctor or pharmacist if you are taking medicines containing sacubitril/valsartan, used to treat heart failure. Vizarsin with food, drink and alcohol Vizarsin can be taken with or without food. However, you may find that Vizarsin takes longer to start working if you take it with a heavy meal. Drinking alcohol can temporarily impair your ability to get an erection. To get the maximum benefit from your medicine, you are advised not to drink excessive amounts of alcohol before taking Vizarsin. Pregnancy and breast-feeding Vizarsin is not indicated for use by women. Driving and using machines Vizarsin can cause dizziness and can affect vision. You should be aware of how you react to Vizarsin before you drive or use machinery. Vizarsin contains lactose and sodium If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicinal product. This medicine contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially sodium- free .
Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure. The recommended starting dose is 50 mg. You should not take Vizarsin more than once a day. You should take Vizarsin about one hour before you plan to have sex. Swallow the tablet whole with a glass of water. If you feel that the effect of Vizarsin is too strong or too weak, talk to your doctor or pharmacist. Vizarsin will only help you to get an erection if you are sexually stimulated. The amount of time Vizarsin takes to work varies from person to person, but it normally takes between half an hour and one hour. You may find that Vizarsin takes longer to work if you take it with a heavy meal. If Vizarsin does not help you to get an erection, or if your erection does not last long enough for you to complete sexual intercourse you should tell your doctor. If you take more Vizarsin than you should You may experience an increase in side effects and their severity. Doses above 100 mg do not increase the efficacy. You should not take more tablets than your doctor tells you to. Contact your doctor if you take more tablets than you should. If you have any further questions on the use of this medicine, ask your doctor or pharmacist.
Seizures or fits - this occurs rarely Other side effects: Very common (may affect more than 1 in 10 people): headache. Common (may affect up to 1 in 10 people): nausea, facial flushing, hot flush (symptoms include a sudden feeling of heat in your upper body), indigestion, colour tinge to vision, blurred vision, visual disturbance, stuffy nose and dizziness. Uncommon (may affect up to 1 in 100 people): vomiting, skin rash, eye irritation, bloodshot eyes /red eyes, eye pain, seeing flashes of light, visual brightness, light sensitivity, watery eyes, pounding heartbeat, rapid heartbeat, high blood pressure, low blood pressure, muscle pain, feeling sleepy, reduced sense of touch, vertigo, ringing in the ears, dry mouth, blocked or stuffy sinuses, inflammation of the lining of the nose (symptoms include runny nose, sneezing and stuffy nose), upper abdominal pain, gastro-oesophageal reflux disease (symptoms include heartburn), presence of blood in urine, pain in the arms or legs, nosebleed, feeling hot and feeling tired. Rare (may affect up to 1 in 1000 people): fainting, stroke, heart attack, irregular heartbeat, temporary decreased blood flow to parts of the brain, feeling of tightening of the throat, numb mouth, bleeding at the back of the eye, double vision, reduced sharpness of vision, abnormal sensation in the eye, swelling of the eye or eyelid, small particles or spots in your vision, seeing halos around lights, dilation of the pupil of the eye, discolouration of the white of the eye, penile bleeding, presence of blood in semen, dry nose, swelling of the inside of the nose, feeling irritable and sudden decrease or loss of hearing. From post-marketing experience cases of unstable angina (a heart condition) and sudden death have been reported rarely. Of note, most but not all, of the men who experienced these side effects had heart problems before taking this medicine. It is not possible to determine whether these events were directly related to Vizarsin. Reporting of side effects If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children. Do not use this medicine after the expiry date which is stated on the box and blister after EXP. The expiry date refers to the last day of that month. This medicine does not require any special storage conditions. Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.
The other ingredients are: Tablet core: microcrystalline cellulose (E460), calcium hydrogen phosphate, croscarmellose sodium, hypromellose (E464), magnesium stearate (E470b). Film coating: lactose monohydrate, hypromellose (E464), titanium dioxide (E171), triacetin (E1518). See section 2 Vizarsin contains lactose and sodium . What Vizarsin looks like and contents of the pack Vizarsin 25 mg film-coated tablets are white, oblong and marked 25 on one side. Vizarsin 25 mg film-coated tablets are available in boxes of 1 film-coated tablet in blisters and also in boxes of 4 x 1, 8 x 1 or 12 x 1 film-coated tablet in a perforated unit dose blisters. Not all pack sizes may be marketed. Marketing Authorisation Holder and Manufacturer KRKA, d.d., Novo mesto, marje ka cesta 6, 8501 Novo mesto, Slovenia For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder: Belgi /Belgique/Belgien KRKA Belgium, SA. T l/Tel: + 32 (0) 487 50 73 Lietuva UAB KRKA Lietuva Tel: + 370 5 236 27
Te .: + 359 (02) 962 34 Luxembourg/Luxemburg KRKA Belgium, SA. T l/Tel: + 32 (0) 487 50 73 62 (BE) esk republika KRKA R, s.r.o. Tel: + 420 (0) 221 115 Magyarorsz g KRKA Magyarorsz g Kereskedelmi Kft. Tel.: + 36 (1) 355 8Danmark KRKA Sverige AB Tlf: + 46 (0)8 643 67 66 (SE) Malta E. J. Busuttil Ltd. Tel: + 356 21 445 Deutschland TAD Pharma GmbH Tel: + 49 (0) 4721 606-0 Nederland KRKA Belgium, SA. Tel: + 32 (0) 487 50 73 62 (BE) Eesti KRKA, d.d., Novo mesto Eesti filiaal Tel: + 372 (0) 6 671 Norge KRKA Sverige AB Tlf: + 46 (0)8 643 67 66 (SE)
KRKA
: + 30 2100101 sterreich KRKA Pharma GmbH, Wien Tel: + 43 (0)1 66 24 Espa a KERN PHARMA, S.L. Tel: + 34 93 700 25 Polska KRKA-POLSKA Sp. z o.o. Tel.: + 48 (0)22 573 7France KRKA France Eurl T l: + 33 (0)1 57 40 82 Portugal KRKA Farmac utica, Sociedade Unipessoal Lda. Tel: + 351 (0)21 46 43 Hrvatska KRKA - FARMA d.o.o. Tel: + 385 1 6312 Rom nia KRKA Romania S.R.L., Bucharest Tel: + 4 021 310 66 Ireland KRKA Pharma Dublin, Ltd. Tel: + 353 1 413 3Slovenija KRKA, d.d., Novo mesto Tel: + 386 (0) 1 47 51 sland LYFIS ehf. S mi: + 354 534 3Slovensk republika KRKA Slovensko, s.r.o. Tel: + 421 (0) 2 571 04 Italia KRKA Farmaceutici Milano S.r.l. Tel: + 39 02 3300 8Suomi/Finland KRKA Finland Oy Puh/Tel: + 358 20 754 5 KI.PA. (PHARMACAL) LIMITED : + 357 24 651 Sverige KRKA Sverige AB Tel: + 46 (0)8 643 67 66 (SE) Latvija KRKA Latvija SIA Tel: + 371 6 733 86 United Kingdom (Northern Ireland) KRKA Pharma Dublin, Ltd. Tel: + 353 1 413 3This leaflet was last revised in Detailed information on this medicine is available on the European Medicines Agency web site:
Entry 1 - fullUrl = Composition/composition-en-4f21ade1d3a44922f890a931e55ca9a9
Resource Composition:
Generated Narrative: Composition composition-en-4f21ade1d3a44922f890a931e55ca9a9
Language: en
Profile: Composition (ePI)
identifier:
http://ema.europa.eu/identifier
/1 film-coated tablet: EU/1/09/551/001status: Final
type: Package Leaflet
category: Raw
date: 2022-02-16 13:28:17+0000
author: Organization ACME industry
title: TEST PURPOSES ONLY - vizarsin
Attesters
Mode Time Official 2022-02-16 13:28:17+0000
Entry 2 - fullUrl = MedicinalProductDefinition/mp4f21ade1d3a44922f890a931e55ca9a9
Resource MedicinalProductDefinition:
Generated Narrative: MedicinalProductDefinition mp4f21ade1d3a44922f890a931e55ca9a9
identifier:
http://ema.europa.eu/identifier
/1 film-coated tablet: EU/1/09/551/001type: Medicinal Product
domain: Human use
status: active
legalStatusOfSupply: Medicinal product subject to medical prescription
name
productName: Vizarsin 25 mg film-coated tablets
type: Full name
part
part: nan
type: Invented name part
part
part: nan
type: Scientific name part
part
part: nan
type: Strength part
part
part: nan
type: Pharmaceutical dose form part
Usages
Country Jurisdiction Language EU EU en